Detalhe da pesquisa
1.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet
; 393(10183): 1819-1830, 2019 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30955977
2.
Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas.
BMC Cancer
; 14: 100, 2014 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24533441
3.
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
J Clin Oncol
; 41(11): 1986-1991, 2023 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36306479
4.
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
Lung Cancer
; 152: 127-134, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387727
5.
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
Front Oncol
; 11: 709877, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34307179
6.
Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma.
PLoS One
; 8(10): e78649, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24130905